Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium breve SHMB 8001
- Development stage
- Preclinical
- Lead developer
- Shanghai Children’s Hospital
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium breve SHMB 8001 is a novel probiotic strain isolated from human milk, currently being investigated as a live biotherapeutic for the treatment of inflammatory bowel disease (IBD). In preclinical studies using DSS-induced colitis mouse models, the strain demonstrated significant anti-inflammatory properties. Its mechanism of action involves the restoration of intestinal barrier integrity by upregulating tight junction proteins, specifically occludin and claudin-1, and the modulation of the gut microbiota community. Furthermore, SHMB 8001 administration leads to a reduction in the levels of key proinflammatory cytokines, including TNF-α, IL-1β, and IL-6. The development is being led by researchers at Shanghai Children’s Hospital and Shanghai Jiao Tong University.
- Other names
- B. breve SHMB 8001
02
Targets
CLDN1 (Tight junction protein claudin-1)IL10 (Interleukin-10)IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)OCLN (Occludin)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Bifidobacterium breve SHMB 8001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium breve SHMB 8001.